
Sign up to save your podcasts
Or


This week OTM shares the second episode of the three-part series, Hard, produced by our WNYC colleagues at Death, Sex & Money. In this installment, the team dives into the scientific advancements that led to Viagra's FDA approval in 1998. From an unforgettable conference presentation...to an overnight drug study, where an unexpected side effect kept popping up. Also the intentionality around the early marketing of Viagra—when former Senate Majority Leader Bob Dole encouraged men to summon the bravery to talk to their doctors—and how that message has shifted over the years.
You can hear more from Death, Sex & Money here.
On the Media is supported by listeners like you. Support OTM by donating today (https://pledge.wnyc.org/support/otm). Follow our show on Instagram, Bluesky, TikTok and Facebook @onthemedia, and share your thoughts with us by emailing [email protected].
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By WNYC Studios4.6
88578,857 ratings
This week OTM shares the second episode of the three-part series, Hard, produced by our WNYC colleagues at Death, Sex & Money. In this installment, the team dives into the scientific advancements that led to Viagra's FDA approval in 1998. From an unforgettable conference presentation...to an overnight drug study, where an unexpected side effect kept popping up. Also the intentionality around the early marketing of Viagra—when former Senate Majority Leader Bob Dole encouraged men to summon the bravery to talk to their doctors—and how that message has shifted over the years.
You can hear more from Death, Sex & Money here.
On the Media is supported by listeners like you. Support OTM by donating today (https://pledge.wnyc.org/support/otm). Follow our show on Instagram, Bluesky, TikTok and Facebook @onthemedia, and share your thoughts with us by emailing [email protected].
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

91,297 Listeners

43,837 Listeners

38,430 Listeners

6,881 Listeners

26,242 Listeners

4,113 Listeners

4,022 Listeners

8,471 Listeners

3,530 Listeners

4,696 Listeners

113,121 Listeners

2,380 Listeners

16,512 Listeners

670 Listeners

16,525 Listeners

15 Listeners